Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 9Lymphoma, Non-Hodgkin 7Hodgkin Disease 5Lymphoma, Mantle-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Hematologic Diseases 2Breast Neoplasms, Male 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1

Interventions

PROSTVAC 1Nivolumab 1Leukapheresis 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Hormone-Sensitive Prostate Cancer × Leukapheresis × Clear all
NCT03532217 2022-08-05

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

Phase 1 Completed
19 enrolled
Genitourinary

Metastatic Hormone-Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡